IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,063,526 shares of the company's stock after selling 144,774 shares during the period. Federated Hermes Inc. owned about 5.86% of IDEAYA Biosciences worth $130,133,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at approximately $35,000. Daiwa Securities Group Inc. raised its position in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after acquiring an additional 853 shares in the last quarter. Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences in the third quarter valued at $83,000. KBC Group NV boosted its position in shares of IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in shares of IDEAYA Biosciences during the 4th quarter worth $203,000. Hedge funds and other institutional investors own 98.29% of the company's stock.

Analyst Ratings Changes

IDYA has been the subject of several recent analyst reports. Wedbush reiterated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Stephens reaffirmed an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded up $0.52 during trading on Friday, reaching $16.29. The company had a trading volume of 602,620 shares, compared to its average volume of 919,594. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The stock's 50 day moving average price is $19.01 and its two-hundred day moving average price is $24.39. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -4.92 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.